Key Takeaways
- Growth stalled by execution, not demand: Volume growth reached only ~7% in H1, well below the double-digit target, because printing capacity expansion and the Mahad plant both slipped by months. Management says the underlying demand is intact and the missing capacity arrives in Q4.
- Pharma is the big bet, now entering the prove-it phase: 8–10 pharma clients are approved and taking small quantities; two committed products launch in January. The FY26 revenue ambition is ₹30–60 crores, but the division is still loss-making and staff costs are already loaded.
- Gross margin per kg is expanding, EBITDA per kg is not: Gross margin reached ₹86/kg as volumes improved, but EBITDA landed at ~₹36.73/kg because staff costs jumped >29% (pharma hires not yet contributing) and consumables spiked on outsourced IML printing.
- Paint is recovering but commoditizing: H1 paint volume grew 4.9% after a negative prior year, and FY25 is guided to 7–8%. The trade-off: paint pails now have 20–50 suppliers, and Mold-Tek lost some Asian Paints volume on price.
- What to watch next quarter: Whether the January printing and pharma mold arrivals actually convert into the promised Q4 volume step-up, and whether EBITDA/kg begins its climb toward the ₹40 target.
The Capacity Bottleneck That Ate the Year
- Printing consolidation delayed: The plan to bring all IML printing under one roof in Hyderabad was meant to cut consumables costs and speed up new label development. Only 70% of machines have moved; the remaining 30% cannot be shifted without halting production for 1–2 weeks, so the move waits on new machines arriving in January.
- IML development slowed growth directly: Because printing capacity was constrained, Mold-Tek could not develop new IML labels as fast as the market required. Management estimates growth would have been at least 10% without this bottleneck.
- Mahad plant delayed by local approvals: Pollution and approval issues pushed the Mahad plant start from the original timeline to September/October, and even then only in a small way. ABG has agreed to supplies from Satara as a bridge for the next few quarters.
- Panipat ramp-up is staggered: Qpack supplies from the North began in October/November; real quantities start end of December; full IML containers from January; food and dairy products from March–April.
- Printing capacity resolves by April: 60–70% additional IML printing capacity is being added by January–February, with the last machine in April. After that, management says printing constraints are "completely eliminated."
Rao: "In the paint and FMCG, most of the products are well established, especially come to paint pails, those paint pails standards have become normal. They are like commoditized. So, there are at least 20, 30, 40 suppliers or even 50 suppliers who are able to produce paint buckets to a reasonable quality and reasonable consistency."
Pharma: The Thesis, the Traction, and the Cost
- The competitive pitch is speed, not scale: Mold-Tek is positioning itself as faster than incumbents at new product development and mold turnaround, using its injection-molding DNA to achieve lower cycle times. In EV tubes, management claims no competitor yet has IML capability.
- Client approvals are stacking up: 8–10 pharma companies have approved facilities and products, including MSN, Marksans, Graviti, Pulse, and Bioplus. Another 4–5 are in the audit pipeline, including Sandoz and Alkem. Line trials and extended testing are approved by "more or less all."
- Revenue is still tiny but has a line of sight: At least two clients began taking one or two products in volume from October. One major order received from Marksans; another product under development starts December/January. Two products have committed capacity buyback and launch in January.
- The cost is already in the P&L: Staff costs rose >29% YoY partly because pharma division people were added but are not yet contributing; pharma capacity utilization is barely 10%. Consumables also spiked on outsourced IML printing while the in-house facility was delayed.
- FY26 ambition is wide: Management guided minimum ₹30–35 crores pharma topline, with a stretch of ₹50–60 crores. At full capacity, current investments could support ₹80–100 crores. Even 1–2% of the ₹5,000 crore pharma packaging market would be ~₹100 crores.
- The onboarding cycle is long but finite: The full process (audit, line trials, stability testing, commercial quotes, small lots, then volumes) takes 12–16 months, not 3–5 years. That means clients being courted now convert through FY26.
Rao: "The point what Mold-Tek is trying to drive to pharma companies is our ability to develop new products faster than anybody else. Even the leaders in pharma packaging, we are in a position to meet or exceed them in terms of new product development."
Segment-Level Performance
| Segment | H1 Trend | Commentary |
|---|---|---|
| Paint | ▲ Recovering | H1 volume +4.9% after a negative prior year; FY25 guided to 7–8% (down from 10%). Grasim (ABG) volumes expected stronger in H2. Realization declined on lower raw material prices and mandatory RCP usage. |
| Lubes | ▼ Soft | Down ~2.5% in H1; the industry is stagnant at ±2% annually, and last year was an aberration with good growth. |
| Food & FMCG | ▬ Muted | Growth limited to ~5.2% because Mold-Tek is absent in the North. Competition in small products in the South. North facility starts contributing from January (food) and March–April (dairy, ice cream). |
| Pharma | ▬ Nascent | Revenue negligible in H1; 8–10 clients approved, small quantities started in October. Material contribution expected only from Q4. |
- Asian Paints volume loss: Management acknowledged some volume loss from Asian Paints due to pricing pressure and capacity constraints on the printing side (IML and HTL). Once capacities are in place from Q4, Mold-Tek can be more competitive.
- Quick commerce opportunity shelved: Management explored supplying Swiggy and Zomato but cited logistical challenges and said "it's not moving much" and "they didn't attempt that later."
Margins: Gross Up, EBITDA Stuck
- Gross margin per kg improved to ₹86, sustainable because as volumes improve across all plants, per-kg conversion and production costs come down.
- EBITDA per kg landed at ~₹36.73, well below the ₹40/kg that management says would have been achievable but for the staff and consumables cost overruns. Full-year EBITDA is guided to ~₹38/kg.
- The staff cost bridge: Panipat and Cheyyar plants have moved from 20–35% utilization to 40–50%, which helps gross margin, but pharma staff additions (near-zero revenue contribution) and other project hires are a net drag.
- The path to ₹40/kg: Management expects to reach ₹40/kg in Q1 of next year, with that level as the minimum for FY26, as pharma volumes begin to absorb the fixed staff cost and printing consolidation reduces consumables leakage.
- Asset turnover is depressed: Currently below 2x due to high investments not yet utilized; historically 2–2.5x. Management expects to cross 2.5x going forward as pharma and Panipat assets start generating revenue.
Capex Cycle: Heavy Spend, Early Innings
- FY25 capex: ₹85–90 crores, with overall pharma investment close to ₹100 crores by year-end. An additional ₹10–15 crores may be spent on pharma this year.
- FY26 capex tentatively lower: Management offered a preliminary range of ₹50–60 crores but stressed it "can't comment today" and will provide clarity only toward year-end.
- Grasim capacity expansion: Capacity across three plants is being raised from ~5,000 tons per annum to 7,500–8,000 tons by March, with machines, robots, and molds arriving from January.
- Mahad replacement: An alternative location (or the same location) plant will be set up in the next 2–3 quarters; until then, supplies continue from Satara.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Printing consolidation complete | Remaining 30% of machines moved once new machines arrive | January |
| Pharma capacity utilization | Reach at least 25–30% | From Q4 FY25 |
| Pharma monthly run-rate | Cross ₹1–2 crores per month | From January |
| Two committed pharma products launch | Products cleared by clients with capacity buyback commitment | January |
| Panipat full IML containers | Full-fledged IML container production begins | January |
| Panipat food and dairy products | Ice cream and dairy packaging manufacturing begins | March–April |
| FY25 paint volume growth | 7–8% for full year | FY25 |
| FY25 overall volume growth | Double-digit (down from 15% ambition) | FY25 |
| FY25 EBITDA per kg | Land around ₹38/kg | FY25 |
| FY25 capex | ₹85–90 crores | FY25 |
| Grasim capacity expansion | 5,000 TPA to 7,500–8,000 TPA | By March |
| IML printing capacity | 60–70% additional capacity; last machine in April | January–April |
| Pharma FY26 revenue | Minimum ₹30–35 crores, stretch ₹50–60 crores | FY26 |
| EBITDA per kg recovery | Reach ₹40/kg minimum | Q1 FY26 |
| FY26 volume growth | 12–15% overall | FY26 |
| FY26 capex (tentative) | ₹50–60 crores, subject to revision | FY26 |
| Mahad alternative plant | Set up in same or alternative location | Next 2–3 quarters |
| Asset turnover | Cross 2.5x | Going forward (undated) |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue mix | 47% paint, 20% lubes, 32.4% Food & Qpack combined, 0.5% pharma |
| Paint revenue growth | +14% YoY |
| Lubes revenue growth | +0.9% YoY |
| Food & FMCG revenue growth | +3.43% YoY |
| Qpack revenue growth | +44.5% YoY |
| Gross margin per kg | ₹86, expanded |
| EBITDA per kg | ₹36.73 currently; expected to land around ₹38 for full year |
| IML share of total products | 72.57%, up from 66.7% last year |
| Pharma sales | ~₹1 crore in Q2; October alone ₹70-75 lakhs |
| H1 volume growth — Paint | +4.9% (was negative last year) |
| H1 volume growth — Lubes | -2.5% (was positive last year) |
| H1 volume growth — Food & FMCG | +5.2% |
| H1 volume growth — Qpack | +39.7% |
| Full-year volume growth guidance | Close to 10% (earlier 15%); FY26 expected 12% to 15% |
| Full-year paint segment growth guidance | 7% to 8% (earlier ~10%) |
| CAPEX committed/ spent in H1 FY25 | ₹62 crores spent; another ₹31 crores committed; full year expected ₹85-90 crores |
| Pharma investment total by end FY25 | Close to ₹100 crores (₹34 crores this year, ₹55 crores prior two years) |
| Pharma revenue expectation FY25 | ₹30 crores to ₹50 crores |
| Pharma revenue expectation FY26 | Minimum ₹30-35 crores, could reach ₹50-60 crores |
| Grasim/ABG H1 volumes | ~1,500-1,600 tons; H2 expected 2,000+ tons |
| Grasim capacity | ~5,000 tons per annum currently; expanding to 7,500-8,000 tons by March |
| Asset turnover ratio | Below 2 currently; historically 2-2.5 |
| FY26 CAPEX preliminary view | ₹50-60 crores as of today |